Organogenesis Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

• Organogenesis Holdings Inc ORGO.OQ reported a quarterly adjusted loss of 10 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 4 cents. The mean expectation of three analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -8 cents to -3 cents per share.

• Revenue fell 22.4% to $101.01 million from a year ago; analysts expected $103.40 million.

• Organogenesis Holdings Inc's reported EPS for the quarter was a loss of 10 cents​.

• The company reported a quarterly loss of $12.2 million.

• Organogenesis Holdings Inc shares had risen by 23.0% this quarter and gained 40.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 51.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Organogenesis Holdings Inc is $7.00, about 35.4% above its last closing price of $4.52

This summary was machine generated from LSEG data August 8 at 03:48 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)